Abemaciclib for certain recurrent ovarian or endometrial cancers
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 study tests abemaciclib, a targeted pill treatment, for recurrent ovarian or endometrial cancer that shows specific tumor genetic patterns. It may help slow or control cancer growth in people whose tumor matches the required test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian epithelial cancer (including fallopian tube or primary peritoneal) OR endometrial cancer confirmed by pathology
- Your tumor must pass specific genetic testing through the study’s molecular tumor board (including CDK4/6 activation features; and for endometrial cancer, endometrioid type with hormone receptors and no CCNE amplification or RB loss)
- You’ve had at least one prior chemotherapy treatment for your recurrent cancer
- You can take pills by mouth, and you’re well enough for treatment (ECOG performance status 0–2)
- Your blood counts and key labs meet minimum levels (including enough neutrophils, platelets, and hemoglobin) and you’re recovered from recent chemotherapy or radiation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether abemaciclib combined with standard hormone (endocrine) therapy can better control metastatic breast cancer in people age 70 and older. It may help if your cancer has already grown despite prior hormone therapy and/or other cancer medicines.
This trial tests whether taking two oral medications (letrozole and abemaciclib) after standard chemotherapy can help keep advanced or recurrent endometrial cancer from coming back. It is for people whose cancer is estrogen receptor-positive and has certain favorable genetic features.
This Phase 2 study tests abemaciclib, a targeted cancer medicine, in people with advanced solid tumors that have specific gene changes related to cyclin D or CDK4/6. The goal is to see how well it controls tumors when standard treatments don’t work or aren’t available.
This Phase 1 trial studies whether adding abemaciclib to olaparib can treat women with recurrent platinum-resistant ovarian cancer. It aims to find a safe dose and see how well the combination can control the cancer.
This trial tests whether adding a targeted drug (abemaciclib) to standard treatment helps prevent breast cancer from coming back again after a local recurrence in women with HR-positive, HER2-negative breast cancer.
This Phase 2 study tests whether adding medicines to standard hormone therapy (letrozole) can control endometrial cancer that has come back, spread, or stopped responding to usual treatments. It also explores whether extra drugs (metformin or gedatolisib) improve results for certain patient groups.
Hear when a new Recurrent Endometrial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.